"Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious successors (biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic and clinical utility. Pharmacists are the primary health care professionals who will provide advice to physicians, other health practitioners and patients on these drugs as governments and other third party payers attempt to contain their costs by ...
Read More
"Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious successors (biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic and clinical utility. Pharmacists are the primary health care professionals who will provide advice to physicians, other health practitioners and patients on these drugs as governments and other third party payers attempt to contain their costs by introducing interchangeable products"--
Read Less
